Papp, Kim A <br/><br/>
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research  01 2018 
 - 1-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1016/j.jval.2017.05.025  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--therapeutic use<br/>Adult<br/>Anti-Inflammatory Agents--therapeutic use<br/>Anti-Inflammatory Agents, Non-Steroidal--therapeutic use<br/>Clinical Trials, Phase III as Topic<br/>Etanercept--therapeutic use<br/>Female<br/>Humans<br/>Male<br/>Propensity Score<br/>Psoriasis--drug therapy<br/>Quality of Life<br/>Randomized Controlled Trials as Topic<br/>Severity of Illness Index<br/>Treatment Outcome